Skip to content
    MRK
    Earnings call· Dec 2024(Q4 FY24)

    Merck & Co., Inc. MRK

    Feb 4, 2025 Source

    Executive summary

    Merck & Co. Q4 FY24 — Strong Growth Offset by GARDASIL China Headwinds

    Merck delivered strong Q4 FY24 results, driven by robust oncology and Animal Health performance, alongside promising new product launches. However, significant headwinds from GARDASIL in China, due to elevated inventory and soft consumer demand, led to a temporary pause in shipments and the withdrawal of the long-term $11 billion sales target for the vaccine. Despite this, the company expresses high confidence in its diversified pipeline and future growth drivers, particularly post-KEYTRUDA LOE, with strategic investments in R&D and business development continuing.

    Highlights

    5
    • Total company revenues increased 9% ex-FX to $15.6 billion in Q4 FY24.

    • KEYTRUDA sales grew 21% to $7.8 billion in Q4 FY24, driven by metastatic and early-stage indications.

    • WINREVAIR contributed $200 million in sales in Q4 FY24, with approximately 5,200 new patients prescribed since launch.

    • Animal Health business delivered strong performance with 13% sales growth in Q4 FY24.

    • Pipeline advancements include over $50 billion of potential revenue opportunity from 20 potential new growth drivers.

    Concerns

    3
    • GARDASIL sales decreased 18% to $1.6 billion in Q4 FY24 due to lower demand and elevated channel inventory in China.

    • Shipments of GARDASIL to China are temporarily paused from February through at least midyear 2025.

    • Medicare Part D redesign is expected to have a negative impact of approximately $400 million on 2025 sales, primarily affecting WINREVAIR and small molecule oncology products.

    Guidance & targets

    17
    CategoryTargetConfidence
    Full-year 2025 Revenue
    $64.1 billion and $65.6 billion
    high materiality
    High
    Full-year 2025 Revenue Growth
    2% to 4%
    high materiality
    High
    Full-year 2025 Revenue Growth (ex-GARDASIL China & FX)
    7% to 9%
    high materiality
    High
    Full-year 2025 GARDASIL China Sales
    no further shipments at the low end and less than $1 billion at the high end
    high materiality
    High
    Full-year 2025 Gross Margin
    approximately 82.5%
    medium materiality
    High
    Full-year 2025 Operating Expenses
    $25.4 billion and $26.4 billion
    medium materiality
    High
    Full-year 2025 Other Expense
    $300 million and $400 million
    low materiality
    High
    Full-year 2025 Tax Rate
    16% and 17%
    medium materiality
    High
    Full-year 2025 EPS
    $8.88 to $9.03
    high materiality
    High
    Full-year 2025 EPS impact from LaNova payment
    approximately $0.09 negative
    low materiality
    High
    Full-year 2025 EPS impact from FX
    approximately $0.35 negative
    low materiality
    High
    Long-term GARDASIL sales target
    Withdrawn
    high materiality
    Low
    Share Repurchase Authorization
    Increased by $10 billion to $12 billion total
    medium materiality
    High
    Share Repurchases 2025
    modest level
    low materiality
    High
    Medicare Part D redesign impact on 2025 sales
    approximately $400 million negative
    medium materiality
    High
    First half 2025 Revenue
    roughly flat year-over-year
    medium materiality
    High
    Second half 2025 Revenue
    strong year-over-year growth
    medium materiality
    High

    Segment performance

    2
    SegmentRevenueYoYQoQMargin
    Human Health
    Sustained momentum, driven primarily by oncology.
    8%
    Animal Health
    Delivered strong performance.
    Livestock growth: higher demand for poultry, sales from recently acquired aqua portfolio from Elanco, priceCompanion animal sales growth: price
    13%

    Operational metrics

    23
    Total Company Revenues
    $15.6Bup 7% reported, 9% ex-FX
    Q4 FY24

    Total company revenues.

    People Reached with Medicines and Vaccines
    nearly 0.5 billion
    FY24

    Including through donations.

    KEYTRUDA Sales
    $7.8Bup 21%
    Q4 FY24

    Driven by continued robust global demand.

    WELIREG Sales
    $160Mmore than doubling
    Q4 FY24

    Strong growth in broader oncology portfolio.

    GARDASIL Sales
    $1.6Bdown 18%
    Q4 FY24

    Due to lower demand in China.

    CAPVAXIVE Sales
    $50M
    Q4 FY24

    Driven by demand from the retail pharmacy channel.

    WINREVAIR Sales
    $200M
    Q4 FY24

    Steady growth from ongoing launch.

    WINREVAIR New Patients (since launch)
    approximately 5,200
    since launch

    Total new patients prescribed since launch.

    WINREVAIR Commercial Product Access
    approximately 80%
    current

    Percentage of patients receiving commercial product.

    Gross Margin
    80.8%up 3.6 percentage points
    Q4 FY24

    Non-GAAP gross margin.

    Operating Expenses
    $7.4B
    Q4 FY24

    Non-GAAP operating expenses.

    Operating Expenses Growth (ex-charges)
    10%
    Q4 FY24

    Reflecting strategic investments.

    Other Expense
    $5M
    Q4 FY24

    Non-GAAP other expense.

    Tax Rate
    16.2%
    Q4 FY24

    Non-GAAP tax rate.

    EPS
    $1.72
    Q4 FY24

    Non-GAAP earnings per share.

    Shares Outstanding
    approximately 2.53 billion
    FY25 assumption

    Assumed for full year 2025 guidance.

    KEYTRUDA Wholesaler Inventory Buy-in
    $200M
    Q4 FY24

    U.S. sales benefited from wholesaler inventory buy-in.

    Medicare Part D Redesign Impact
    $400Mnegative impact
    FY25

    Expected negative impact on sales.

    JANUVIA List Price Change
    lowered
    beginning of 2025

    To align with net prices.

    Unvaccinated Women in China
    100 million-plus
    current

    Potential market for GARDASIL.

    Unvaccinated Males in China
    about 200 million
    current

    Potential market for GARDASIL with new indication.

    People on Statins Not at Goal
    70%
    current

    Unmet need in cardiometabolic space.

    Pipeline Revenue Opportunity
    over $50B
    long-term

    Potential revenue from diversified pipeline.

    Industry KPIs

    6
    MetricValueDetails
    EPS$1.72USD
    Gross margin80.8%%
    Revenue net sales$15.6BUSD
    Effective tax rate16.2%%
    Pricing price realizationlowered
    Clinical trial efficacy safety datastatistically significant reduction

    Product announcements

    1
    ProductTypeDetails
    CAPVAXIVElaunch

    Deals & partnerships

    6
    LaNova MedicinesExclusive global license agreement for a novel investigational PD-1/VEGF bispecific antibody (MK-2010).

    Plan to explore the full potential of MK-2010 across multiple tumor types in a global patient population.

    Hansoh PharmaLicensing agreement for an investigational preclinical oral small molecule GLP-1 receptor agonist (MK-4082).

    Will be entering the clinic this year. Well positioned to advance oral small molecule GLP-1 agonist-containing combinations.

    HarpoonAcquisition of Harpoon.

    Added a T-cell engager to the pipeline.

    EyeBioAcquisition of EyeBio.

    Added important new biologic candidates.

    CuronAsset from Curon.

    Added important new biologic candidates.

    Kelun-BiotechCollaboration for Sac-TMT, a TROP2-directed antibody drug conjugate.

    Sac-TMT is being developed through a collaboration with Kelun-Biotech with 10 ongoing Phase III studies across multiple solid tumors.

    Risks & headwinds

    3
    GARDASIL China demand and inventoryQ4 2024 (impact), February through at least midyear (shipment pause)

    GARDASIL sales were $1.6 billion, a decrease of 18%, due to lower demand in China. overall channel inventory remains elevated at above-normal levels.

    Mitigation: temporarily pause shipments to China beginning this month and through at least midyear

    Medicare Part D redesign2025

    negative impact to sales of approximately $400 million

    Mitigation: partially offset with some volume benefit as patients stay on therapy

    Soft consumer spending in ChinaQ4 2024 and ongoing

    increased pressure on discretionary consumer spending, including across the vaccine space more broadly

    Mitigation: allowing the underlying demand that is still there to absorb the Zhifei inventory

    What to watch in Q1 FY25

    5

    WINREVAIR January sales recovery

    next quarter
    Currentsome impact to prescription volumes due to the holiday season
    TargetJanuary returning to the levels we would have expected it to be

    Why it matters

    Indicates the underlying demand strength and commercial trajectory of a key new growth driver.

    As we look at what's happening in January, actually, we're seeing January returning to the levels we would have expected it to be. And so as we look at 2025, we do actually see this as a strong growth contributor, and all of the fundamentals we see support that.

    Q&A highlights

    8

    Can WINREVAIR grow 100% year-over-year from Q4 trends into end of 2025, given some claims data suggesting a weaker start to the year?

    Management expressed unchanged confidence in WINREVAIR's potential and growth, noting that January sales are returning to expected levels, supporting strong growth in 2025.

    As we look at what's happening in January, actually, we're seeing January returning to the levels we would have expected it to be. And so as we look at 2025, we do actually see this as a strong growth contributor, and all of the fundamentals we see support that.

    asked by Umer Raffat · answered by Robert Davis

    2 min read6 chapters

    Detailed Narrative

    01

    GARDASIL China Re-evaluation and Strategic Pause

    Merck has temporarily paused shipments of GARDASIL to China from February through at least midyear 2025 due to challenging market dynamics, elevated channel inventory, and soft consumer spending. This decision aims to accelerate inventory reduction and support the financial position of commercialization partner Zhifei. While the long-term $11 billion sales target for GARDASIL has been withdrawn due to uncertain timing of📎 economic recovery in China, Merck remains committed to maximizing the significant long-term opportunity in the region, especially with the recent male indication approval.

    02

    WINREVAIR Clinical and Commercial Momentum

    WINREVAIR, the first and only activin signaling inhibitor for pulmonary arterial hypertension (PAH), demonstrated overwhelming efficacy in the Phase III ZENITH trial, leading to its early stoppage. The HYPERION study was also stopped early due to loss of clinical equipoise. Commercial launch is progressing well, with $200 million in Q4 sales, approximately 5,200 new patients prescribed since launch, and strong access. Initial international launches are also performing positively, reinforcing confidence in its growth expectations.

    03

    Diversified Pipeline for Long-Term Growth

    Merck has significantly diversified its pipeline, nearly tripling late-phase assets over the past three years across oncology, cardiometabolic, immunology, HIV, ophthalmology, infectious disease, and vaccines. These programs represent over $50 billion in potential revenue opportunity, with 20 potential new growth drivers identified, almost all having blockbuster potential. This diversification is key to navigating the KEYTRUDA LOE period and sustaining long-term value creation.

    04

    Oncology Pipeline Expansion

    The oncology pipeline continues to deepen beyond KEYTRUDA, with significant progress in antibody-drug conjugates (ADCs) from Kelun and Daiichi Sankyo, small molecule targeted therapies, and the individualized neoantigen therapy (INT) partnership with Moderna. The recent addition of a T-cell engager from Harpoon and a PD-1/VEGF bispecific antibody from LaNova further enhances the portfolio. Subcutaneous pembrolizumab is also expected to be filed and potentially launched in 2025.

    05

    Cardiometabolic and Infectious Disease Progress

    In cardiometabolic, Merck anticipates Phase III readouts for its oral PCSK9 inhibitor, enlicitide, in April, July, and August 2025, aiming to achieve similar efficacy to antibody PCSK9 inhibitors. A licensing agreement for an oral GLP-1 receptor agonist (MK-4082) with Hansoh Pharma further strengthens this area. In infectious diseases, the FDA has set a June 10 target action date for clesrovimab, a long-acting monoclonal antibody for RSV in infants, and positive Phase III results for islatravir-based regimens in HIV were announced.

    06

    Capital Allocation and Shareholder Returns

    Merck's capital allocation strategy prioritizes investments in the business and pipeline, maintaining a commitment to increasing dividends over time. The company recently increased its share repurchase authorization by $10 billion to a total of $12 billion, providing flexibility, though a modest level of repurchases is expected in 2025 given investment opportunities. The company remains committed to not having excess cash build on its balance sheet.

    AI-generated summary of the company’s earnings call. Not investment advice.